Eli Lilly and Company (NEO: LLY)

Market Cap	958.78B
Revenue (ttm)	55.20B
Net Income (ttm)	11.31B
Shares Out	n/a
EPS (ttm)	12.50
PE Ratio	84.79
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,968
Average Volume	69,756
Open	27.25
Previous Close	27.06
Day's Range	27.07 - 27.89
52-Week Range	23.25 - 36.42
Beta	n/a
RSI	40.64
Earnings Date	Jan 31, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the comp...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 43,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: LLY

Financial Performance

In 2023, Eli Lilly and Company's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.

Financial numbers in USD